Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are availabl...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Basel
Springer Basel
2014, 2014
|
| Edition: | 1st ed. 2014 |
| Series: | Milestones in Drug Therapy
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- Current Pharmacotherapy for COPD
- The preclinical pharmacology of indacaterol
- The design of the indacaterol molecule
- The early clinical development of Indacaterol
- INHANCE: An adaptive confirmatory study with dose selection at interim
- Phase III clinical efficacy studies – lung function
- Phase III Clinical Efficacy of Indacaterol
- Patient-centered Outcomes
- The history and performance of the Breezhaler device
- What does the future hold for the therapy of COPD?